Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs AT&T Inc. — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while AT&T Inc. trades at $23.14 (market cap $156.58B). The key difference: AT&T Inc. is far larger — about 20.8× Spyre Therapeutics Inc. Common Stock's market cap, and AT&T Inc. pays a 4.86% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and AT&T Inc. for 118 Days on average.
| SYRE | T | |
|---|---|---|
Market Cap | $7.52B | $156.58B |
Volume | 1,441,031 | 46,597,672 |
Sector | Health | Media |
52-Week High | $108.92 | $29.10 |
52-Week Low | $22.18 | $20.49 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $6.52B | $301.90B |
Dividend Yield | — | 4.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
AT&T (T) trades at $23.08, up 2.62% today, with strong fundamentals including a P/E of 7.54 and net income margin of 16.94%. Recent earnings beat expectations, with Q2 2026 EPS of $0.65 versus $0.59 expected. Technical indicators show a bearish overall signal despite bullish oscillators. The company maintains robust cash flow with $15.12B net cash flow in 2025 and recently announced a $3B fiber deal with Corning to support AI infrastructure growth.
Outlook remains mixed with analyst consensus price target of $27.39 offering 19% upside potential, though technical weakness and competitive pressures pose risks. The stock's 4% dividend yield provides income support, but debt levels and legacy revenue declines require monitoring. Fiber expansion and wireless growth present opportunities amid challenging market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
